Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiology of the Heart: The Cardiac Cycle01:18

Physiology of the Heart: The Cardiac Cycle

9.2K
The cardiac cycle describes the events from one heartbeat to the next. It includes three main phases: diastole, atrial systole, and ventricular systole, all driven by changes in chamber pressures and the function of heart valves.
Diastole: The Relaxation Phase
During diastole, all four heart chambers relax. The atrioventricular (AV) valves open, and the semilunar valves close. This phase sees the lowest chamber pressures, promoting ventricular filling. Venous blood enters the heart through the...
9.2K
Cardiac Output I:Effect of Heart Rate on Cardiac Output01:19

Cardiac Output I:Effect of Heart Rate on Cardiac Output

2.6K
Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart...
2.6K
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

971
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
971
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.1K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.1K
Anatomy of the Heart01:27

Anatomy of the Heart

119.7K
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
119.7K
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

687
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
687

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between the TNF-α-308G/A and TNF-α-238G/A polymorphisms and systemic lupus erythematosus susceptibility: an updated meta-analysis.

Frontiers in medicine·2026
Same author

Barriers to Optimization of Medical Therapy and the Role of Checklist-Based Decision Support in Heart Failure.

Journal of the American Heart Association·2026
Same author

Circulating Progenitor Cells, Regenerative Capacity and Cognition: Evidence From 2 Community-Based Cohorts.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Ag Nanocluster-Triggered Lattice Oxygen Activation in Amorphous Sulfide Matrices for Superior Oxygen Evolution.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Care Models for the Genetic Evaluation of Dilated Cardiomyopathy at Sites of the DCM Consortium.

medRxiv : the preprint server for health sciences·2026
Same author

Dyslipidemia and therapies after heart transplantation: Current evidence and future directions.

Journal of clinical lipidology·2026

Related Experiment Video

Updated: Jan 31, 2026

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
09:25

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

Published on: May 8, 2020

8.4K

Cardiac Lymphatics Predict Survival After Heart Transplantation.

Sydney C Ginn1,2, Anamaria Dragan2, Benoit A Niclou2

  • 1Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta GA USA.

Journal of the American Heart Association
|January 30, 2026
PubMed
Summary

Reduced cardiac lymphatics after heart transplant are linked to increased cardiac allograft vasculopathy (CAV) and higher patient mortality. Lymphatic area may predict transplant outcomes and risk for CAV.

Keywords:
cardiac allograft vasculopathyheart transplantationlymphatics

More Related Videos

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K
Murine Heterotopic Heart Transplant Technique
10:27

Murine Heterotopic Heart Transplant Technique

Published on: July 8, 2014

17.7K

Related Experiment Videos

Last Updated: Jan 31, 2026

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
09:25

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

Published on: May 8, 2020

8.4K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K
Murine Heterotopic Heart Transplant Technique
10:27

Murine Heterotopic Heart Transplant Technique

Published on: July 8, 2014

17.7K

Area of Science:

  • Cardiology
  • Transplant Immunology
  • Vascular Biology

Background:

  • Cardiac allograft vasculopathy (CAV) is a primary cause of late graft loss and reduced survival post-orthotopic heart transplantation (OHT).
  • Severed cardiac lymphatics during OHT may disrupt homeostasis, potentially influencing CAV development and outcomes.
  • This study investigates the relationship between cardiac lymphatic variations and CAV in OHT patients.

Purpose of the Study:

  • To examine if variations in cardiac lymphatics influence CAV development and outcomes after OHT.
  • To determine if lymphatic area in endomyocardial biopsies can serve as a predictive marker for CAV and mortality.
  • To explore the potential therapeutic role of lymphangiogenic pathways in improving OHT outcomes.

Main Methods:

  • A single-center, retrospective case-control study involving 50 OHT patients.
  • Endomyocardial biopsies were collected at 1 and 5 years post-OHT.
  • CAV severity was graded using angiograms, and lymphatic density (lymphatics/mm²) was quantified.

Main Results:

  • A significant inverse correlation was observed between lymphatic area and CAV severity.
  • Patients with lower lymphatic areas one year post-OHT exhibited higher mortality rates (40% vs. 12%).

Conclusions:

  • Reduced cardiac lymphatics are associated with increased CAV and mortality risk in OHT recipients.
  • Lymphatic area quantification may identify patients at higher risk for adverse outcomes.
  • Further research is needed to validate these findings, explore clinical confounders, and investigate therapeutic strategies targeting lymphangiogenesis.